1-2 of 2
Kelly Speth
Close
Save search
Sort by
Journal Articles

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Free
Dasom (Caroline) Lee, Swetha Kambhampati, Maria Silvina Odstrcil Bobillo, Babatunde Adedokun, Mazyar Shadman, Amanda L. Olson, Alex F. Herrera, Catherine J. Lee, Caron A. Jacobson, Matthew Bye, Mehdi Hamadani, Soyoung Kim, Saurabh Dahiya, Zhen-Huan Hu, Kelly Speth, Christina To, Debbie L. Mirjah, Timothy Best, Frederick L. Locke, Nausheen Ahmed, Michael T. Tees, Marcelo C. Pasquini, Sairah Ahmed
Journal: Blood
Blood (2024) 144 (Supplement 1): 526.
https://doi.org/10.1182/blood-2024-199139
Published: 2024
Journal Articles

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Free
Rawan Faramand, Michael D. Jain, Biwei Cao, Xuefeng Wang, Kayla M. Reid, Sae Bom Lee, Salvatore A. Corallo, Meghan A. Menges, Melanie Hidalgo-Vargas, Christina A. Bachmeier, Julio C. Chavez, Bijal D. Shah, Javier Pinilla Ibarz, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Kelly Speth, Qinghua Song, Mike Mattie, Frederick L. Locke, Marco L. Davila
Journal: Blood
Blood (2022) 140 (Supplement 1): 4678–4680.
https://doi.org/10.1182/blood-2022-171084
Published: 2022